Key clinical point: Patients with migraine who recovered from COVID-19 showed an increase in the frequency of headache attacks, level of anxiety, and use of antimigraine drugs.
Major finding: Among patients with migraine, those with vs without a history of COVID-19 showed a significant increase in the frequency of headache attacks (P = .01), level of anxiety (P = .002), and use of antimigraine drugs (P = .04) after recovering from COVID-19, with no significant difference being observed in the headache intensity (P = .51) and the dynamics of the Beck Depression scale score (P = .09).
Study details: Findings are from a retrospective study including 133 patients aged 18-55 years with chronic and episodic migraine and with (n = 95) or without (n = 38) a history of COVID-19.
Disclosures: This study did not receive any funding. The authors declared no potential conflicts of interest.
Source: Hrytsenko O et al. The impact of the COVID-19 pandemic on patients with migraine. SAGE Open Med. 2023 (Apr 28). doi: 10.1177/20503121231170726